In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Scientific advances and new players in adjacent sectors such as big tech open the door for innovative biopharma collaborations.

Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies

Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

COVID-19 Tech Collaborations: Adaptive And Microsoft Map Immune System Responses

A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.

Sleeping With The Enemy? Open Minds Needed For Tech Partnerships

The entry of tech giants Amazon and Alphabet into healthcare has the potential to disrupt the industry, but can established pharma players partner with them in the move towards a customer and data-oriented future? Panelists from Gilead, Merck KGaA, Bristol-Myers Squibb and others deliberated the question at a recent summit.

Cancer Deals That Grabbed Headlines In 2020

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 24 deals with upfront value of at least $100m.

Chapter sponsored by:

It Takes A Village To Raise Novel Medicines

Strategic collaborations are a key component of Rentschler Biopharma's overall strategy, says CEO Frank Mathias.

Download Now

About Rentschler Biopharma

At Rentschler Biopharma, we enable to your product's success by translating medical research into outstanding biopharmaceuticals for the treatment of patients with serious and rare diseases.

Learn More »